Healthcare company Baxter International (NYSE: BAX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less impressive, coming in 1% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 11.4% below analysts’ consensus estimates.

Is now the time to buy BAX? Find out in our full research report (it’s free).

StockStory’s Take

Baxter’s second quarter results were met with a significant negative market reaction following a combination of in-line sales and a notable shortfall in non-GAAP profit. Management attributed the mixed performance primarily to persistent hospital fluid conservation, modest demand in the Medical Products & Therapies and Pharmaceutical segments, and challenges related to product mix. COO Heather Knight highlighted the ongoing effects of lower U.S. patient admissions and evolving hospital protocols as key factors, while also acknowledging a temporary pause in shipments of the Novum IQ infusion pump due to quality feedback. Management’s cautious commentary around operational softness and product-specific disruptions shaped the tone of the quarter.

Looking forward, Baxter’s guidance reflects continued caution, with lowered full-year profit expectations and a tempered sales outlook. Management cited uncertainty around the resumption of Novum IQ shipments and the pace at which hospitals return to historical IV fluid usage patterns. CFO Joel Grade emphasized that the company’s projections now assume minimal improvement in fluid conservation and no further Novum shipments for the remainder of the year, stating, "The low end of our current guidance assumes we don't resume shipments for Novum prior to the end of the year." Leadership also pointed to ongoing cost management, new leadership transition, and targeted investments in innovation as central to navigating ongoing headwinds.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to persistent volume headwinds in key product lines, product quality actions, and a cautious customer environment, while noting sequential improvement in select areas.

• Hospital fluid conservation persists: Hospitals maintained elevated IV fluid conservation levels due to recent supply disruptions and slower-than-expected changes in clinical protocols. Management noted only slight improvement in hospital behavior, which continues to weigh on volume recovery and manufacturing absorption.
• Novum IQ shipment pause: Baxter temporarily paused shipments and installations of its Novum IQ infusion pump platform to address feedback from quality and customer experience reviews. The company is working through device corrections and interim mitigations, aiming to resume shipments later this year pending progress.
• Advanced Surgery and Care & Connectivity strength: These segments remained bright spots, with Advanced Surgery products and Care & Connectivity Solutions delivering solid demand and international growth. The Vizient partnership to expand U.S. IV fluid reserves was highlighted as a positive development for supply assurance.
• Injectables and anesthesia softness: Pharmaceuticals, particularly U.S. injectables and inhaled anesthesia, experienced weaker demand. This was driven by changes in hospital protocols, the absence of large government orders, and a shift toward alternative administration methods following recent disruptions.
• Expense management and portfolio focus: Management emphasized cost discipline, actions to reduce stranded costs post-divestiture, and a streamlined focus after completing the Vantive sale. TSA income from transitional services agreements provided some offset to margin pressure, but overall mix and volume challenges remained significant.

Drivers of Future Performance

Baxter’s outlook is shaped by ongoing headwinds in hospital purchasing patterns, the pace of recovery in key product volumes, and the timing of new product rollouts.

• Novum IQ uncertainty: Management’s guidance range assumes the possibility that Novum IQ infusion pump shipments do not resume for the rest of the year, introducing risk to infusion therapy segment growth and overall margin recovery.
• Hospital fluid usage trends: The company expects persistent hospital fluid conservation to limit volume recovery through the second half, impacting manufacturing efficiency and sales. Only modest improvement is assumed in the updated outlook, reflecting customer caution and gradual protocol changes.
• Cost controls and leadership transition: Ongoing initiatives to reduce stranded costs and streamline operations are expected to partially offset volume and mix headwinds. The appointment of incoming CEO Andrew Hider is intended to bring operational discipline and fresh strategic focus, but management cautioned that tangible impact will take time as he ramps up.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the status and timing of Novum IQ infusion pump shipment resumption and related customer feedback, (2) whether hospitals begin to lift IV fluid conservation practices and return to historical usage patterns, and (3) progress on reducing stranded costs and executing operational improvements under new CEO Andrew Hider. The pace of international segment growth and any recovery in pharmaceuticals will also be key markers of execution.

Baxter currently trades at $24.14, down from $28.07 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.